This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Klein, K. O. Articles by Cutler, G. B. Search for Related Content PubMed PubMed Citation Articles by Klein, K. O. Articles by Cutler, G. B., Jr.

Use of an Ultrasensitive Recombinant Cell Bioassay to Determine Estrogen Levels in Girls with Precocious Puberty Treated with a Luteinizing Hormone-Releasing Hormone Agonist

A. I. duPont Hospital for Children (K.O.K.), Wilmington, Delaware 19899; and the Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892

Address all correspondence and requests for reprints to: Dr. Karen Oerter Klein, Department of Clinical Science, A. I. duPont Hospital for Children, P.O. Box 269, 1600 Rockland Road, Wilmington, Delaware 19899.

Although treatment of girls with precocious puberty should ideally restore estradiol levels to the normal prepubertal range, treatment effectiveness has usually been monitored by gonadotropin levels because estradiol RIAs have lacked sufficient sensitivity to monitor treatment effectiveness. We hypothesized that a recently developed ultrasensitive recombinant cell bioassay for estradiol would have sufficient sensitivity to demonstrate a dose-dependent suppression of estradiol during LH-releasing hormone agonist treatment and to determine whether currently used doses are able to suppress estradiol levels to the normal prepubertal range.

Twenty girls with central precocious puberty were assigned randomly to receive deslorelin for 9 months at a dose of 1, 2, or 4 µg/kg·day. A significant dose-response relationship was observed, with mean ± SD estradiol levels of 16.7 ± 6.1, 7.9 ± 1.6, and 6.5 ± 0.7 pmol/L at the doses of 1, 2, and 4 µg/kg·day, respectively (P < 0.01). The highest dose suppressed estradiol levels to just above the 95% confidence limits for normal prepubertal girls (<0.07–6.3 pmol/L).

We conclude that the ultrasensitive bioassay for estradiol has sufficient sensitivity for monitoring the response to LH-releasing hormone agonist treatment of central precocious puberty. Additionally, the observation that the deslorelin dose of 4 µg/kg·day did not fully restore estradiol levels to the normal prepubertal range suggests that some girls with precocious puberty may require higher doses to receive the maximal benefit of treatment. We suggest that restoration of estradiol levels to the normal prepubertal range should be the ultimate biochemical measure of efficacy, as estradiol is the key hormone that accelerates growth rate, bone maturation rate, and breast development in girls with precocious puberty.

This article has been cited by other articles:

				C. Ankarberg-Lindgren and E. Norjavaara A purification step prior to commercial sensitive immunoassay is necessary to achieve clinical usefulness when quantifying serum 17 -estradiol in prepubertal children Eur. J. Endocrinol., January 1, 2008; 158(1): 117 - 124. [Abstract] [Full Text] [PDF]

				M. Weise, A. Flor, K. M. Barnes, G. B. Cutler Jr., and J. Baron Determinants of Growth during Gonadotropin-Releasing Hormone Analog Therapy for Precocious Puberty J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 103 - 107. [Abstract] [Full Text] [PDF]

				K. O. Klein, M. Janfaza, J. A. Wong, and R. J. Chang Estrogen Bioactivity in Fo-Ti and Other Herbs Used for Their Estrogen-Like Effects as Determined by a Recombinant Cell Bioassay J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4077 - 4079. [Abstract] [Full Text] [PDF]

				M. Lampit, A. Golander, H. Guttmann, and Z.'e. Hochberg Estrogen Mini-Dose Replacement during GnRH Agonist Therapy in Central Precocious Puberty: A Pilot Study J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 687 - 690. [Abstract] [Full Text] [PDF]

				C. Ankarberg-Lindgren, M. Elfving, K. A. Wikland, and E. Norjavaara Nocturnal Application of Transdermal Estradiol Patches Produces Levels of Estradiol That Mimic Those Seen at the Onset of Spontaneous Puberty in Girls J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3039 - 3044. [Abstract] [Full Text] [PDF]

				A Single Sample Subcutaneous Luteinizing Hormone (LH)-Releasing Hormone (LHRH) Stimulation Test for Monitoring LH Suppression in Children with Central Precocious Puberty Receiving LHRH Agonists J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4536 - 4540. [Abstract] [Full Text]

				K. Oerter Klein Editorial: Precocious Puberty: Who Has It? Who Should Be Treated? J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 411 - 414. [Full Text]